Crinetics Pharmaceuticals Inc. logo

Crinetics Pharmaceuticals (CRNX) stock

CRNX · Crinetics Pharmaceuticals Inc. · NASDAQ

Website

What is the latest news on CRNX stock?

13D/Gago
Amendment: SEC Form SCHEDULE 13G/A filed by Crinetics Pharmaceuticals Inc.

SCHEDULE 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

All CRNX news

When does Crinetics Pharmaceuticals report earnings?

Crinetics Pharmaceuticals last reported on Aug 4, 2026, the date it announced on Jun 30, 2026. Before that it reported on May 7, 2026 and Feb 26, 2026.

CRNX earnings history

Are insiders buying or selling CRNX?

No CRNX insider has reported a purchase or sale in the last 90 days. The last trade on file: Coelho Rogerio Vivaldi sold $120K, reported on Jul 7, 2026.

CRNX insider trades

Latest news

25 items
News · 26 weeks66+100%
2026-05-31: 32026-06-07: 02026-06-14: 32026-06-21: 82026-06-28: 32026-07-05: 72026-07-12: 02026-07-19: 12026-07-26: 12026-08-02: 52026-08-09: 32026-08-16: 12026-08-23: 22026-08-30: 252026-09-06: 12026-09-13: 02026-09-20: 02026-09-27: 02026-10-04: 02026-10-11: 02026-10-18: 02026-10-25: 02026-11-01: 02026-11-08: 12026-11-15: 22026-11-22: 0
2026-05-312026-11-22
Mix3190d
  • Insider12(39%)
  • SEC Filings11(35%)
  • Other4(13%)
  • 13D/G3(10%)
  • Leadership1(3%)
Activity · 52 weeks12956 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Crinetics Pharmaceuticals Inc. (CRNX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for CRNX, including 3 13D/G filings. The most recent was published Nov 16, 2026.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist that has completed phase II clinical trial for the treatment of acromegaly, as well as completed phase 1 clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist to treat congenital hyperinsulinism, which is in phase 1 clinical trial; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase 1 clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

CRNX FAQ

7 questions
  • What does Crinetics Pharmaceuticals Inc. do?
    Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist that has completed phase II clinical trial for the treatment of acromegaly, as well as completed phase 1 clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide...
  • Where does CRNX stock trade?
    Crinetics Pharmaceuticals Inc. (CRNX) is listed on NASDAQ.
  • What sector and industry is CRNX in?
    Crinetics Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did Crinetics Pharmaceuticals Inc. go public?
    Crinetics Pharmaceuticals Inc. (CRNX) completed its IPO in 2018.
  • What are analysts saying about CRNX?
    Across the last 8 analyst actions on Crinetics Pharmaceuticals Inc., there were 2 upgrades and 0 downgrades. The most recent action was from UBS: Buy with a $55.00 price target on 2026-07-02. Recent price targets range from $36.00 to $68.00.
  • What companies are similar to CRNX?
    Notable peers in the same industry include JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), ABT (Abbott Laboratories), LLY (Eli Lilly and Company), NVO (Novo Nordisk A/S). Compare CRNX side-by-side with any of them on Quantisnow.
  • How can I track CRNX on Quantisnow?
    Quantisnow aggregates Crinetics Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CRNX to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change